Premium
Low dose acetylsalicylic acid and thromboxane release at the site of plug formation in vivo in elderly patients with cardiovascular disease
Author(s) -
THORNGREN M.,
ECKERT B.,
VINGE E.
Publication year - 1990
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1990.tb00141.x
Subject(s) - medicine , thromboxane b2 , aspirin , blood sampling , stroke (engine) , thromboxane , bleeding time , vascular disease , gastroenterology , surgery , anesthesia , platelet , platelet aggregation , mechanical engineering , engineering
. Thromboxane B 2 (TXB 2 ) levels in bleeding time blood and in serum were measured in 13 elderly patients with cardiovascular disease, seven of whom were receiving continuous treatment with low dose acetylsalicylic acid (ASA, 125 mg every second day — 250 mg daily) for prevention of stroke. Blood sampling was performed openly, but assays of TXB 2 were performed by a blinded investigator. In patients treated with ASA, median serum TXB 2 ‐levels were 4% and TXB 2 ‐levels in bleeding‐time blood were < 16% of the corresponding levels in patients without ASA ( P < 0.01). The results show that in elderly atherosclerotic patients very low doses of ASA substantially suppress TXB 2 formation, not only in serum but also at the site of local haemostasis. The extent of suppression is comparable to that previously reported from young healthy subjects.